MA39422A - Modulateurs de cot et procédés d'utilisation associés - Google Patents

Modulateurs de cot et procédés d'utilisation associés

Info

Publication number
MA39422A
MA39422A MA039422A MA39422A MA39422A MA 39422 A MA39422 A MA 39422A MA 039422 A MA039422 A MA 039422A MA 39422 A MA39422 A MA 39422A MA 39422 A MA39422 A MA 39422A
Authority
MA
Morocco
Prior art keywords
modulators
toc
related usage
usage procedures
procedures
Prior art date
Application number
MA039422A
Other languages
English (en)
Other versions
MA39422B1 (fr
Inventor
Elizabeth M Bacon
Gayatri Balan
Chien-Hung Chou
Christopher T Clark
Jeromy J Cottell
Musong Kim
Thorsten A Kirschberg
John O Link
Gary Phillips
Scott D Schroeder
Neil H Squires
Kirk L Stevens
James G Taylor
William J Watkins
Nathan E Wright
Sheila M Zipfel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA39422A publication Critical patent/MA39422A/fr
Publication of MA39422B1 publication Critical patent/MA39422B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

La présente description concerne en général les modulateurs de cot (cancer osaka thyroïde) et les méthodes d'utilisation et de fabrication de celles-ci.
MA39422A 2015-07-06 2016-06-30 Modulateurs de cot et procédés d'utilisation associés MA39422B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189158P 2015-07-06 2015-07-06
US201562269060P 2015-12-17 2015-12-17
EP16738976.6A EP3191470B1 (fr) 2015-07-06 2016-06-30 Modulateurs de cot et procédés d'utilisation associés

Publications (2)

Publication Number Publication Date
MA39422A true MA39422A (fr) 2017-07-19
MA39422B1 MA39422B1 (fr) 2019-03-29

Family

ID=56411943

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39422A MA39422B1 (fr) 2015-07-06 2016-06-30 Modulateurs de cot et procédés d'utilisation associés

Country Status (40)

Country Link
US (6) US20170008905A1 (fr)
EP (3) EP3896064A1 (fr)
JP (5) JP6430060B2 (fr)
KR (5) KR102073641B1 (fr)
CN (3) CN109879859B (fr)
AU (4) AU2016290820B2 (fr)
BR (1) BR102016015656B1 (fr)
CA (1) CA2971640C (fr)
CL (1) CL2017003356A1 (fr)
CO (1) CO2017013351A2 (fr)
CR (1) CR20170599A (fr)
CU (1) CU20170172A7 (fr)
CY (1) CY1121750T1 (fr)
DK (1) DK3191470T3 (fr)
DO (1) DOP2017000311A (fr)
EA (1) EA036788B1 (fr)
EC (1) ECSP17084635A (fr)
ES (2) ES2872076T3 (fr)
HR (1) HRP20190853T1 (fr)
HU (1) HUE043310T2 (fr)
IL (4) IL274568B (fr)
LT (1) LT3191470T (fr)
MA (1) MA39422B1 (fr)
ME (1) ME03425B (fr)
MX (1) MX370984B (fr)
MY (1) MY196173A (fr)
NZ (2) NZ750707A (fr)
PE (1) PE20180462A1 (fr)
PH (2) PH12018500031A1 (fr)
PL (2) PL3191470T3 (fr)
PT (2) PT3456717T (fr)
RS (1) RS58639B1 (fr)
SA (1) SA517381350B1 (fr)
SG (1) SG11201702041PA (fr)
SI (2) SI3191470T1 (fr)
SV (1) SV2017005605A (fr)
TW (3) TWI634112B (fr)
UA (1) UA123010C2 (fr)
UY (1) UY36771A (fr)
WO (1) WO2017007689A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
EP3319955B1 (fr) 2015-07-06 2020-11-25 Gilead Sciences, Inc. Derives de 6-amino-quinoline-3-carbonitrile comme des modulateurs de cot
EP3896064A1 (fr) 2015-07-06 2021-10-20 Gilead Sciences, Inc. Dérivés de 4,6-diamino-quinoline-3-carbonitrile en tant que modulateurs de cancer osaka thyroid (cot) pour le traitement de la maladie de crohn et de la rectocolite hémorragique
WO2018005435A1 (fr) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines utilisées comme modulateurs de cot et leurs méthodes d'utilisation
HUE063811T2 (hu) * 2016-08-19 2024-02-28 Gilead Sciences Inc HIV-vírus-fertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
EA036921B1 (ru) * 2017-02-10 2021-01-15 Джилид Сайэнс, Инк. Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
CN108794516A (zh) * 2017-04-26 2018-11-13 上海时莱生物技术有限公司 硼酸和硼酸酯类化合物及其制备方法和用途
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
JPWO2019065516A1 (ja) * 2017-09-26 2020-09-10 日本曹達株式会社 キノリン化合物および農園芸用殺菌剤
KR102587510B1 (ko) 2018-02-15 2023-10-11 길리애드 사이언시즈, 인코포레이티드 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
WO2019161280A1 (fr) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Procédés et intermédiaires pour préparer un composé thérapeutique utile dans le traitement d'une infection virale par retroviridae
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN110294660B (zh) * 2018-03-23 2021-09-24 中国农业大学 一种含碳碳三键和/或碳氮三键的不饱和有机化合物的还原氘化方法
CN108658996A (zh) * 2018-06-25 2018-10-16 中国药科大学 一种氘代Fiduxosin的制备方法
CA3216031A1 (fr) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Inhibiteurs de capsides pour le traitement du vih
TWI770527B (zh) * 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CN114585619A (zh) 2019-08-29 2022-06-03 爱杜西亚药品有限公司 α-D-吡喃半乳糖苷衍生物
KR20220106165A (ko) 2019-11-26 2022-07-28 길리애드 사이언시즈, 인코포레이티드 Hiv의 예방을 위한 캡시드 억제제
CA3175541A1 (fr) * 2020-03-30 2021-10-07 Gilead Sciences, Inc. Formes solides de (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile un compose inhibiteur de cot
AU2021245924B2 (en) 2020-04-02 2024-02-29 Gilead Sciences, Inc. Process for preparing a Cot inhibitor compound
EP4172157A1 (fr) 2020-06-25 2023-05-03 Gilead Sciences, Inc. Inhibiteurs de capside pour le traitement du vih
TW202300146A (zh) 2021-03-03 2023-01-01 瑞士商愛杜西亞製藥有限公司 經***基-甲基取代的α-D-吡喃半乳糖苷衍生物
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
KR20240019340A (ko) * 2021-06-11 2024-02-14 뉴로내슨트, 아이엔씨. 헤테로시클릭 유형의 친유성 소분자 치료의 지질 제제를 위한 방법 및 조성물
TW202337439A (zh) 2021-12-03 2023-10-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3930837A (en) 1971-12-31 1976-01-06 Ici Australia Limited 3-chloro-5-acetamidaisoquinoline as a herbicide
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
NL7800191A (nl) 1977-01-10 1978-07-12 Ciba Geigy Anthelmintisch preparaat.
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2634438B2 (ja) 1988-07-26 1997-07-23 三井東圧化学株式会社 不斉ビスオキサゾリルピリジン誘導体およびその製造方法
DE4014171A1 (de) 1990-05-03 1991-11-07 Basf Ag Cyanochinolinverbindungen
GB9310700D0 (en) 1993-05-24 1993-07-07 Zeneca Ltd Novel composition
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
NZ503079A (en) 1997-08-28 2002-07-26 Nissan Chemical Ind Ltd Cyanoacrylate-containing antibacterial and antifungal agents, algicides and antifouling agents
DK1097158T3 (da) 1998-07-10 2006-05-29 Massachusetts Inst Technology Ligander til metaller og metalkatalyserede metoder
CN1144786C (zh) * 1998-09-29 2004-04-07 美国氰胺公司 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉
GEP20074230B (en) 2002-03-20 2007-11-12 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
WO2004078176A1 (fr) 2003-03-03 2004-09-16 F. Hoffmann-La Roche Ag Tetrahydroisoquinoleines substituees en position 2,5 et 2,6, utilisees en tant que modulateurs des 5-ht6
KR20060066733A (ko) 2003-08-19 2006-06-16 와이어쓰 홀딩스 코포레이션 4-아미노-3-퀴놀린카보니트릴의 제조방법
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
TW200529846A (en) * 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006124944A1 (fr) 2005-05-18 2006-11-23 Wyeth Inhibiteurs de 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile de la tpl2 kinase et procedes de fabrication et d'utilisation de ceux-ci
CA2608540A1 (fr) 2005-05-18 2006-11-23 Wyeth Inhibiteurs 3-cyanoquinoline de la tpl2 kinase et procedes de production et d'utilisation associes
WO2007050732A1 (fr) 2005-10-28 2007-05-03 Abbott Laboratories DERIVES D’INDAZOLE INHIBANT LE RECEPTEUR TRPVl
MX2008012482A (es) 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
WO2008055950A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Nouveaux inhibiteurs de la glutaminyl-cyclase
CN101583601B (zh) 2007-01-17 2013-06-05 香港科技大学 作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物
GB0820856D0 (en) 2008-11-14 2008-12-24 Univ Leuven Kath Novel inhibitors of flavivirus replication
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
GB0922302D0 (en) * 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
CA2791247C (fr) 2010-03-09 2019-05-14 Dana-Farber Cancer Institute, Inc. Procedes de diagnostic et de traitement du cancer chez des patients ayant ou developpant une resistance a une premiere therapie anticancereuse
RU2600928C2 (ru) * 2010-06-09 2016-10-27 Тяньцзинь Химэй Байо-Тек Ко., Лтд Цианохинолиновые производные
EP2708540B1 (fr) 2011-05-10 2018-07-25 Kyowa Hakko Kirin Co., Ltd. Composé pyrimido-diazépinone
WO2013004652A1 (fr) 2011-07-04 2013-01-10 Bayer Intellectual Property Gmbh Utilisation d'isoquinoléinones, d'isoquinoléinediones, d'isoquinoléinetriones et de dihydroisoquinoléinones substituées ou de leurs sels comme principes actifs contre le stress abiotique des plantes
EP2545964A1 (fr) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité
WO2013062027A1 (fr) 2011-10-27 2013-05-02 大正製薬株式会社 Dérivé azole
CN104105485B (zh) 2011-11-11 2017-04-12 吉利德阿波罗公司 Acc抑制剂和其用途
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
CN103483363B (zh) 2012-06-13 2016-12-21 上海赛迦化工产品有限公司 多样性的手性氨基硼酸及其制备方法和应用
EP2911655A1 (fr) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteurs de la kinase tpl2 pour prévenir ou traiter le diabète et favoriser la survie de cellules
CN103408572B (zh) 2013-07-12 2015-12-02 上海工程技术大学 手性氨基硼酸衍生物及其制备方法和应用
WO2015089170A1 (fr) 2013-12-12 2015-06-18 Kalyra Pharmaceuticals, Inc. Composés d'alkyle bicyclique et synthèse
JP6741343B2 (ja) 2014-03-07 2020-08-19 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー プロペラン誘導体および合成
EP3166938A4 (fr) * 2014-07-11 2018-01-17 Northwestern University Échafaudages 2-imidazolyl-pyrimidine en tant qu'inhibiteurs puissants et sélectifs de l'oxyde nitrique synthase neuronale
CA2961605C (fr) 2014-09-17 2023-01-10 Kalyra Pharmaceuticals, Inc. Composes bicycliques
JP2017528471A (ja) 2014-09-24 2017-09-28 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置する方法
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
ES2842749T3 (es) 2014-12-23 2021-07-14 Gilead Sciences Inc Procesos para preparar inhibidores de ASK1
CN107106873A (zh) 2015-01-09 2017-08-29 吉利德阿波罗公司 用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗
CA2974004A1 (fr) 2015-01-16 2016-07-21 3M Innovative Properties Company Systemes et procedes pour selectionner des actions de reseau pour ameliorer des resultats de grille
EP3319955B1 (fr) * 2015-07-06 2020-11-25 Gilead Sciences, Inc. Derives de 6-amino-quinoline-3-carbonitrile comme des modulateurs de cot
EP3896064A1 (fr) 2015-07-06 2021-10-20 Gilead Sciences, Inc. Dérivés de 4,6-diamino-quinoline-3-carbonitrile en tant que modulateurs de cancer osaka thyroid (cot) pour le traitement de la maladie de crohn et de la rectocolite hémorragique
CN106928198B (zh) 2015-12-31 2020-07-28 成都先导药物开发股份有限公司 磺酰胺衍生物及其制备方法与应用
CA3220447A1 (fr) 2016-03-02 2017-09-08 Gilead Apollo, Llc Formes solides d'un inhibiteur de thienopyrimidinedione acc et leurs procedes de production
WO2017221944A1 (fr) 2016-06-21 2017-12-28 パナソニックヘルスケアホールディングス株式会社 Inhibiteur de catalase et procédé de mesure d'analyte utilisant un inhibiteur de catalase
WO2018005435A1 (fr) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines utilisées comme modulateurs de cot et leurs méthodes d'utilisation
CN106512014A (zh) 2016-10-27 2017-03-22 武汉大学 肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
CA3137479A1 (fr) 2017-03-03 2018-09-07 Gilead Sciences, Inc. Procedes de preparation d'inhibiteurs d'acc et formes solides correspondantes
PL3600309T3 (pl) 2017-03-28 2022-11-07 Gilead Sciences, Inc. Skojarzenia terapeutyczne do leczenia chorób wątroby
CA3059883A1 (fr) 2017-04-12 2018-10-18 Gilead Sciences, Inc. Methodes de traitement d'une maladie hepatique
TWI814744B (zh) 2017-10-06 2023-09-11 美商基利科學股份有限公司 包含acc抑制劑之組合療法
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
US20220143153A1 (en) 2019-03-08 2022-05-12 The Regents Of The University Of California Compositions and methods for treating acne
TWI770527B (zh) 2019-06-14 2022-07-11 美商基利科學股份有限公司 Cot 調節劑及其使用方法
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CA3175541A1 (fr) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Formes solides de (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)-methyl-1-oxo-1,2-dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile un compose inhibiteur de cot
AU2021245924B2 (en) 2020-04-02 2024-02-29 Gilead Sciences, Inc. Process for preparing a Cot inhibitor compound
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法

Also Published As

Publication number Publication date
CA2971640A1 (fr) 2017-01-12
SV2017005605A (es) 2018-07-18
HUE043310T2 (hu) 2019-08-28
ME03425B (fr) 2020-01-20
RS58639B1 (sr) 2019-05-31
PH12018500031B1 (en) 2018-07-09
NZ738525A (en) 2019-03-29
KR20220129667A (ko) 2022-09-23
UA123010C2 (uk) 2021-02-03
TW202114673A (zh) 2021-04-16
PT3191470T (pt) 2019-06-05
IL293770A (en) 2022-08-01
IL293770B2 (en) 2023-07-01
AU2019203122B2 (en) 2020-10-01
CN107922390A (zh) 2018-04-17
ES2872076T3 (es) 2021-11-02
AU2020257055A1 (en) 2020-11-12
JP6430060B2 (ja) 2018-11-28
JP6781221B2 (ja) 2020-11-04
KR102443575B1 (ko) 2022-09-16
PH12020551397A1 (en) 2021-08-16
JP2018520161A (ja) 2018-07-26
CY1121750T1 (el) 2020-07-31
AU2022204050A1 (en) 2022-06-30
EA201792613A1 (ru) 2018-06-29
TWI748539B (zh) 2021-12-01
SI3191470T1 (sl) 2019-04-30
TWI634112B (zh) 2018-09-01
PH12018500031A1 (en) 2018-07-09
MX370984B (es) 2020-01-09
AU2022204050B2 (en) 2024-04-18
KR102073641B1 (ko) 2020-02-05
CN109879859B (zh) 2022-01-25
PT3456717T (pt) 2021-05-26
BR102016015656B1 (pt) 2021-11-03
HRP20190853T1 (hr) 2019-06-28
CR20170599A (es) 2018-02-28
CU20170172A7 (es) 2018-06-05
KR20200013120A (ko) 2020-02-05
JP2019178178A (ja) 2019-10-17
EP3191470B1 (fr) 2019-02-27
JP2021042252A (ja) 2021-03-18
PL3456717T3 (pl) 2021-10-25
IL256433A (en) 2018-02-28
JP2018193405A (ja) 2018-12-06
IL293770B1 (en) 2023-03-01
EP3456717A1 (fr) 2019-03-20
JP7138155B2 (ja) 2022-09-15
CO2017013351A2 (es) 2018-05-21
IL274568B (en) 2022-07-01
SI3456717T1 (sl) 2021-08-31
US11066414B2 (en) 2021-07-20
CA2971640C (fr) 2020-09-22
US20170008905A1 (en) 2017-01-12
US11905299B2 (en) 2024-02-20
KR20190045416A (ko) 2019-05-02
TWI699361B (zh) 2020-07-21
MY196173A (en) 2023-03-17
AU2016290820A1 (en) 2018-01-18
US20180237455A1 (en) 2018-08-23
AU2020257055B2 (en) 2022-03-31
ECSP17084635A (es) 2018-01-31
CL2017003356A1 (es) 2018-07-06
JP6906021B2 (ja) 2021-07-21
IL266995B (en) 2020-05-31
SG11201702041PA (en) 2017-04-27
CN109879859A (zh) 2019-06-14
AU2016290820B2 (en) 2019-03-07
JP2022082816A (ja) 2022-06-02
DOP2017000311A (es) 2018-01-15
NZ750707A (en) 2023-09-29
EA036788B1 (ru) 2020-12-21
IL256433B (en) 2019-06-30
EP3456717B1 (fr) 2021-03-17
US9878995B2 (en) 2018-01-30
EP3896064A1 (fr) 2021-10-20
SA517381350B1 (ar) 2021-03-11
BR102016015656A2 (pt) 2020-09-24
KR101974793B1 (ko) 2019-05-02
PE20180462A1 (es) 2018-03-06
US20200123172A1 (en) 2020-04-23
US20170152240A1 (en) 2017-06-01
MA39422B1 (fr) 2019-03-29
TW201908305A (zh) 2019-03-01
ES2734713T3 (es) 2019-12-11
IL266995A (en) 2019-07-31
UY36771A (es) 2017-01-31
TW201712005A (zh) 2017-04-01
WO2017007689A1 (fr) 2017-01-12
EP3191470A1 (fr) 2017-07-19
US20190248807A1 (en) 2019-08-15
LT3191470T (lt) 2019-05-10
DK3191470T3 (en) 2019-04-15
IL274568A (en) 2020-06-30
CN107922390B (zh) 2019-05-10
KR20240008398A (ko) 2024-01-18
KR20180022982A (ko) 2018-03-06
AU2019203122A1 (en) 2019-05-30
CN114380799A (zh) 2022-04-22
PL3191470T3 (pl) 2019-08-30
US20230002407A1 (en) 2023-01-05
MX2017004737A (es) 2017-06-19

Similar Documents

Publication Publication Date Title
MA39422A (fr) Modulateurs de cot et procédés d'utilisation associés
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MA43187A (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA40671B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
CR20200483A (es) Anticuerpos anti-hla-g y utilización de los mismos
DOP2023000172A (es) Moduladores de cot y métodos de uso de los mismos
MA39126B1 (fr) Synthèse d'enantiomère de progestérone et d'intermédiaires de celui-ci
MA39411A (fr) Synthèse de l'énantiomère de la progestérone et ses intermédiaires
MA39355A1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA39141A1 (fr) Anticorps anti-tau(ps422) humanisés et leurs méthodes d'utilisation
MA39078A1 (fr) Anticorps anti-cd3 et méthodes d'utilisation
EA202092495A1 (ru) МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MA38105B1 (fr) Immunoglobulines hétérodimères